Adults will lead psychobiotic supplements sales through 2036 with a 54.0% share of the end user segment in 2026. The market was valued at USD 150.00 million in 2025 and is expected to reach USD 219.00 million by 2036, creating an incremental opportunity of USD 63.75 million between 2026 and 2036.